Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis

被引:0
|
作者
Bhatia, Neal [1 ]
Gold, Linda Stein [2 ]
Kircik, Leon H. [3 ,4 ,5 ,6 ,7 ]
Schreiber, Rhonda [8 ]
机构
[1] Therapeut Clin Res, San Diego, CA 92161 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA
[5] Phys Skin Care PLLC, Louisville, KY USA
[6] DermResearch PLLC, Louisville, KY USA
[7] Skin Sci PLLC, Louisville, KY USA
[8] Mayne Pharma LLC, Raleigh, NC USA
关键词
OINTMENT; CREAM;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective:To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with "treatment success," defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator's Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving "Treatment Success" in 25.3% and 30.7% vs 3.9% and 74% (P<0.001) in Studies 1 and 2, respectively. Pruritus scores statistically improved by over 30% in HBP-Foam treated subjects. In addition, these subjects experienced a significant reduction in the clinical signs of psoriasis (plaque elevation, scaling, and erythema). In contrast, in the vehicle groups the decrease in psoriasis-related signs was generally not observed. Safety outcomes were unremarkable and similar in both the HBP-Foam and vehicle treatment groups. Conclusions:These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 50 条
  • [1] Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis
    Pariser, David
    Bukhalo, Michael
    Guenthner, Scott
    Kempers, Steven
    Shideler, Stephen
    Gold, Linda Stein
    Tschen, Eduardo
    Berg, Jim
    Ferdon, Mary Beth
    Dromgoole, Syd
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (03) : 234 - 240
  • [2] Two multicenter, randomized, double-blind, parallel group comparison studies of halobetasol propionate lotion, 0.05% versus vehicle lotion in adult subjects with plaque psoriasis
    Pariser, David
    Bukhalo, Michael
    Guenthner, Scott
    Kempers, Steven
    Shideler, Stephen
    Gold, Linda Stein
    Tschen, Eduardo
    Berg, James
    Ferdon, Mary Beth
    Piacquadio, Daniel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB280 - AB280
  • [3] A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis
    Kerdel, Francisco A.
    Draelos, Zoe D.
    Tyring, Stephen K.
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 333 - 339
  • [4] A DOUBLE-BLIND, MULTICENTER COMPARISON OF 0.05-PERCENT HALOBETASOL PROPIONATE OINTMENT AND 0.05-PERCENT CLOBETASOL PROPIONATE OINTMENT IN PATIENTS WITH CHRONIC, LOCALIZED PLAQUE PSORIASIS
    GOLDBERG, B
    HARTDEGEN, R
    PRESBURY, D
    SMITH, EH
    YAWALKAR, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1145 - 1148
  • [5] A DOUBLE-BLIND, VEHICLE-CONTROLLED PAIRED COMPARISON OF HALOBETASOL PROPIONATE CREAM ON PATIENTS WITH PLAQUE PSORIASIS
    KATZ, HI
    GROSS, E
    BUXMAN, M
    PRAWER, SE
    SCHWARTZEL, EH
    GIBSON, JR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1175 - 1178
  • [6] A DOUBLE-BLIND, MULTICENTER COMPARISON BETWEEN 0.05-PERCENT HALOBETASOL PROPIONATE OINTMENT AND 0.05-PERCENT BETAMETHASONE DIPROPIONATE OINTMENT IN CHRONIC PLAQUE PSORIASIS
    MENSING, H
    KORSUKEWITZ, G
    YAWALKAR, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1149 - 1152
  • [7] EVALUATION OF HALOBETASOL PROPIONATE OINTMENT IN THE TREATMENT OF PLAQUE PSORIASIS - REPORT ON 2 DOUBLE-BLIND, VEHICLE-CONTROLLED STUDIES
    BERNHARD, J
    WHITMORE, C
    GUZZO, C
    KANTOR, I
    KALB, RE
    ELLIS, C
    URBACH, F
    SCHWARTZEL, EH
    GIBSON, JR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1170 - 1174
  • [8] A Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Calcipotriene Foam, 0.005%, vs Vehicle Foam in the Treatment of Plaque-type Psoriasis of the Scalp
    Feldman, Steven R.
    Eastman, William J.
    Brundage, Thomas
    Mills, Mary
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (03) : 300 - 306
  • [9] A COMPARATIVE, MULTICENTER, DOUBLE-BLIND TRIAL OF 0.05-PERCENT HALOBETASOL PROPIONATE OINTMENT AND 0.1-PERCENT BETAMETHASONE VALERATE OINTMENT IN THE TREATMENT OF PATIENTS WITH CHRONIC, LOCALIZED PLAQUE PSORIASIS
    BLUM, G
    YAWALKAR, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (06) : 1153 - 1156
  • [10] A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Lebwohl, Mark G.
    Pariser, David M.
    Alexander, Binu J.
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (03) : 197 - 204